Audio Journal of Cardiovascular Medicine: Reduced Mortality and Repeat MI with Enoxaparin for Patients with ST Elevation Myocardial Infarction

REFERENCE: European Heart Journal Advanced On-Line Publication April 24th, 2007
Enoxaparin could be the new standard anti-thrombotic therapy for patients receiving fibrinolysis for ST elevation myocardial infarction. This finding is from the double-blind EXTRACT-TIMI 25 Trial which compared the low molecular weight heparin with unfractionated heparin and saw a consistent treatment superiority from enoxaparin with a reduction in repeat myocardial infarction and mortality. Sarah Maxwell spoke with the principal investigator Harvey White at the Auckland City Hospital in New Zealand.